AI assistant
Pasithea Therapeutics Corp. — Director's Dealing 2024
Jun 14, 2024
35389_dirs_2024-06-14_23049c07-5bc8-49f1-9c19-820b36d0d656.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Pasithea Therapeutics Corp. (KTTA)
CIK: 0001841330
Period of Report: 2024-06-12
Reporting Person: Novak Alfred J (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-06-12 | Common Stock | A | 750 | $5.61 | Acquired | 750 | Direct |
| 2024-06-13 | Common Stock | A | 2750 | $5.62 | Acquired | 3500 | Direct |
Footnotes
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.60 to $5.65 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.55 to $5.70 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.